Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma
Authors:
- 27 August 2020
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 61 (14) , 3378-3386
Abstract
Extended post-therapy long-term survival of patients with diffuse large B cell lymphoma (DLBCL) may also lead to an increase of late adverse events. We retrospectively investigated the frequency and clinical manifestation of second primary malignancy (SPM) after rituximab-containing immunochemotherapy in patients with DLBCL treated at seven institutes belonging to the Kyoto Clinical Hematology Study Group (KOTOSG) from the perspective of the existence of past or synchronous cancer history. In a median follow-up period of 899 days, 69 SPMs were observed in 58 of 809 patients. The most frequent SPM was gastric cancer, followed by lung cancer and colorectal cancer. The cumulative incidence of SPM increased steadily over time and was not significantly influenced by the presence or absence of past or synchronous cancer history. Our study suggests the need for careful attention to SPM in patients with DLBCL in daily practice.Keywords
This publication has 33 references indexed in Scilit:
- Risk for second malignancies in non-Hodgkin’s lymphoma survivors: a meta-analysisAnnals of Oncology, 2011
- Second Malignancy Risks After Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: Differences by Lymphoma SubtypeJournal of Clinical Oncology, 2010
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'AdulteBlood, 2010
- Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort studyHaematologica, 2008
- Risk of Subsequent Solid Tumors After Non-Hodgkin's Lymphoma: Effect of Diagnostic Age and Time Since DiagnosisJournal of Clinical Oncology, 2008
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- The risk of secondary malignancies over 30 years after the treatment of non‐Hodgkin lymphomaCancer, 2006
- Risk of Second Malignancy After Non-Hodgkin's Lymphoma: A British Cohort StudyJournal of Clinical Oncology, 2006
- Incidence and mortality from stomach cancer in Japan, Slovenia and the USAInternational Journal of Cancer, 2001
- Bladder and Kidney Cancer Following Cyclophosphamide Therapy for Non-Hodgkin's LymphomaJNCI: Journal of the National Cancer Institute, 1995